You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

Experimental drug to treat depression granted fast-track status

Alkermes plc may be best known for its drugs that treat addiction and schizophrenia -- and for a 2011 trans-Atlantic deal in which it bought an Irish drug maker, doubled in size, and moved from Waltham to Dublin.

But the biotechnology company got a new lift Wednesday, saying the Food and Drug Administration had granted fast-track status for its experimental medicine to combat depression, intended for patients who don’t respond to standard therapies.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week